Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Identifieur interne : 004308 ( Ncbi/Merge ); précédent : 004307; suivant : 004309Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Auteurs : David V. Glidden [États-Unis] ; Kathleen Mulligan ; Vanessa Mcmahan ; Peter L. Anderson ; Juan Guanira ; Suwat Chariyalertsak ; Susan P. Buchbinder ; Linda Gail Bekker ; Mauro Schechter ; Beatriz Grinsztejn ; Robert M. GrantSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
Descripteurs français
- KwdFr :
- Absorptiométrie photonique, Adulte, Agents antiVIH (administration et posologie), Agents antiVIH (effets indésirables), Densité osseuse (), Emtricitabine (administration et posologie), Femelle, Homosexualité masculine, Humains, Infections à VIH (), Infections à VIH (traitement médicamenteux), Maladies osseuses (), Mâle, Observance thérapeutique, Prophylaxie pré-exposition, Ténofovir (administration et posologie), Ténofovir (effets indésirables), Études de suivi.
- MESH :
- administration et posologie : Agents antiVIH, Emtricitabine, Ténofovir.
- effets indésirables : Agents antiVIH, Ténofovir.
- traitement médicamenteux : Infections à VIH.
- Absorptiométrie photonique, Adulte, Densité osseuse, Femelle, Homosexualité masculine, Humains, Infections à VIH, Maladies osseuses, Mâle, Observance thérapeutique, Prophylaxie pré-exposition, Études de suivi.
English descriptors
- KwdEn :
- Absorptiometry, Photon, Adult, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (adverse effects), Bone Density (drug effects), Bone Diseases (chemically induced), Bone Diseases (therapy), Emtricitabine (administration & dosage), Female, Follow-Up Studies, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (prevention & control), Homosexuality, Male, Humans, Male, Patient Compliance, Pre-Exposure Prophylaxis, Tenofovir (administration & dosage), Tenofovir (adverse effects).
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Emtricitabine, Tenofovir.
- chemical , adverse effects : Anti-HIV Agents, Tenofovir.
- chemically induced : Bone Diseases.
- complications : HIV Infections.
- drug effects : Bone Density.
- drug therapy : HIV Infections.
- prevention & control : HIV Infections.
- therapy : Bone Diseases.
- Absorptiometry, Photon, Adult, Female, Follow-Up Studies, Homosexuality, Male, Humans, Male, Patient Compliance, Pre-Exposure Prophylaxis.
Abstract
Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.
DOI: 10.1097/QAI.0000000000001475
PubMed: 28639995
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D09
- to stream PubMed, to step Curation: 000D09
- to stream PubMed, to step Checkpoint: 000D09
Links to Exploration step
pubmed:28639995Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.</title><author><name sortKey="Glidden, David V" sort="Glidden, David V" uniqKey="Glidden D" first="David V" last="Glidden">David V. Glidden</name><affiliation wicri:level="2"><nlm:affiliation>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Mulligan, Kathleen" sort="Mulligan, Kathleen" uniqKey="Mulligan K" first="Kathleen" last="Mulligan">Kathleen Mulligan</name></author><author><name sortKey="Mcmahan, Vanessa" sort="Mcmahan, Vanessa" uniqKey="Mcmahan V" first="Vanessa" last="Mcmahan">Vanessa Mcmahan</name></author><author><name sortKey="Anderson, Peter L" sort="Anderson, Peter L" uniqKey="Anderson P" first="Peter L" last="Anderson">Peter L. Anderson</name></author><author><name sortKey="Guanira, Juan" sort="Guanira, Juan" uniqKey="Guanira J" first="Juan" last="Guanira">Juan Guanira</name></author><author><name sortKey="Chariyalertsak, Suwat" sort="Chariyalertsak, Suwat" uniqKey="Chariyalertsak S" first="Suwat" last="Chariyalertsak">Suwat Chariyalertsak</name></author><author><name sortKey="Buchbinder, Susan P" sort="Buchbinder, Susan P" uniqKey="Buchbinder S" first="Susan P" last="Buchbinder">Susan P. Buchbinder</name></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda Gail" last="Bekker">Linda Gail Bekker</name></author><author><name sortKey="Schechter, Mauro" sort="Schechter, Mauro" uniqKey="Schechter M" first="Mauro" last="Schechter">Mauro Schechter</name></author><author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name></author><author><name sortKey="Grant, Robert M" sort="Grant, Robert M" uniqKey="Grant R" first="Robert M" last="Grant">Robert M. Grant</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28639995</idno><idno type="pmid">28639995</idno><idno type="doi">10.1097/QAI.0000000000001475</idno><idno type="wicri:Area/PubMed/Corpus">000D09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D09</idno><idno type="wicri:Area/PubMed/Curation">000D09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D09</idno><idno type="wicri:Area/PubMed/Checkpoint">000D09</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D09</idno><idno type="wicri:Area/Ncbi/Merge">004308</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.</title><author><name sortKey="Glidden, David V" sort="Glidden, David V" uniqKey="Glidden D" first="David V" last="Glidden">David V. Glidden</name><affiliation wicri:level="2"><nlm:affiliation>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Mulligan, Kathleen" sort="Mulligan, Kathleen" uniqKey="Mulligan K" first="Kathleen" last="Mulligan">Kathleen Mulligan</name></author><author><name sortKey="Mcmahan, Vanessa" sort="Mcmahan, Vanessa" uniqKey="Mcmahan V" first="Vanessa" last="Mcmahan">Vanessa Mcmahan</name></author><author><name sortKey="Anderson, Peter L" sort="Anderson, Peter L" uniqKey="Anderson P" first="Peter L" last="Anderson">Peter L. Anderson</name></author><author><name sortKey="Guanira, Juan" sort="Guanira, Juan" uniqKey="Guanira J" first="Juan" last="Guanira">Juan Guanira</name></author><author><name sortKey="Chariyalertsak, Suwat" sort="Chariyalertsak, Suwat" uniqKey="Chariyalertsak S" first="Suwat" last="Chariyalertsak">Suwat Chariyalertsak</name></author><author><name sortKey="Buchbinder, Susan P" sort="Buchbinder, Susan P" uniqKey="Buchbinder S" first="Susan P" last="Buchbinder">Susan P. Buchbinder</name></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda Gail" last="Bekker">Linda Gail Bekker</name></author><author><name sortKey="Schechter, Mauro" sort="Schechter, Mauro" uniqKey="Schechter M" first="Mauro" last="Schechter">Mauro Schechter</name></author><author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name></author><author><name sortKey="Grant, Robert M" sort="Grant, Robert M" uniqKey="Grant R" first="Robert M" last="Grant">Robert M. Grant</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (adverse effects)</term><term>Bone Density (drug effects)</term><term>Bone Diseases (chemically induced)</term><term>Bone Diseases (therapy)</term><term>Emtricitabine (administration & dosage)</term><term>Female</term><term>Follow-Up Studies</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (prevention & control)</term><term>Homosexuality, Male</term><term>Humans</term><term>Male</term><term>Patient Compliance</term><term>Pre-Exposure Prophylaxis</term><term>Tenofovir (administration & dosage)</term><term>Tenofovir (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Absorptiométrie photonique</term><term>Adulte</term><term>Agents antiVIH (administration et posologie)</term><term>Agents antiVIH (effets indésirables)</term><term>Densité osseuse ()</term><term>Emtricitabine (administration et posologie)</term><term>Femelle</term><term>Homosexualité masculine</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Maladies osseuses ()</term><term>Mâle</term><term>Observance thérapeutique</term><term>Prophylaxie pré-exposition</term><term>Ténofovir (administration et posologie)</term><term>Ténofovir (effets indésirables)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Emtricitabine</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Emtricitabine</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bone Diseases</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Bone Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Female</term><term>Follow-Up Studies</term><term>Homosexuality, Male</term><term>Humans</term><term>Male</term><term>Patient Compliance</term><term>Pre-Exposure Prophylaxis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Absorptiométrie photonique</term><term>Adulte</term><term>Densité osseuse</term><term>Femelle</term><term>Homosexualité masculine</term><term>Humains</term><term>Infections à VIH</term><term>Maladies osseuses</term><term>Mâle</term><term>Observance thérapeutique</term><term>Prophylaxie pré-exposition</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28639995</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>22</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.</ArticleTitle><Pagination><MedlinePgn>177-182</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000001475</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A metabolic substudy of 498 participants in a randomized, placebo-controlled HIV prevention trial of oral coformulated TDF with emtricitabine (TDF/FTC, Truvada) for HIV pre-exposure prophylaxis (PrEP) enrolling a global sample of men who have sex with men and trans women.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants underwent dual X-ray absorptiometry to quantify bone mineral density (BMD) in the hip and spine during PrEP and at 2 visits after stopping (median of 23 and 79 weeks post-PrEP, respectively). Results are stratified by pharmacologic measure of TDF/FTC adherence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference in change in hip/spine BMD at any time point between placebo and those with low adherence. Adherent participants had a mean (standard error) BMD change at TDF/FTC discontinuation of -1.02% (0.24) in the hip and -1.84% (0.36) in the spine. After stop, annualized BMD increases of 1.13% per year (0.27) in hip and 1.81% per year (0.36) in spine BMD were observed in adherent participants compared with 0.19% (0.16) and 0.74% (0.21) in the placebo group, respectively (P = 0.003, both comparisons). On average, BMD returned to baseline levels by 1 year after PrEP stop. Recovery was consistent across age, baseline BMD z-score, and treatment duration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mean BMD returns to baseline levels within 12-18 months after TDF-based PrEP discontinuation in both hip and spine with consistency across participant subgroups.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov NCT00458393.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glidden</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulligan</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>McMahan</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Guanira</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chariyalertsak</LastName><ForeName>Suwat</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Buchbinder</LastName><ForeName>Susan P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Bekker</LastName><ForeName>Linda Gail</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Schechter</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grinsztejn</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UM1 AI069476</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AI120819</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI106499</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068619</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI064002</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AI122908</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical><Chemical><RegistryNumber>G70B4ETF4S</RegistryNumber><NameOfSubstance UI="D000068679">Emtricitabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>HIV AIDS (Auckl). 2011;3:53-9</RefSource><PMID Version="1">22096407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94</RefSource><PMID Version="1">26866954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Clin Risk Manag. 2010 Feb 02;6:41-7</RefSource><PMID Version="1">20169035</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2014 Sep;14(9):820-9</RefSource><PMID Version="1">25065857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):205-10</RefSource><PMID Version="1">21522014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2016 Jan 2;387(10013):53-60</RefSource><PMID Version="1">26364263</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):423-34</RefSource><PMID Version="1">22784038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):399-410</RefSource><PMID Version="1">22784037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2012 Sep 12;4(151):151ra125</RefSource><PMID Version="1">22972843</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Densitom. 2012 Oct-Dec;15(4):422-33</RefSource><PMID Version="1">22819139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19816</RefSource><PMID Version="1">25397560</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Jun 15;381(9883):2083-90</RefSource><PMID Version="1">23769234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 Jun 27;385(9987):2606-15</RefSource><PMID Version="1">25890673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(8):e23688</RefSource><PMID Version="1">21897852</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Dec 30;363(27):2587-99</RefSource><PMID Version="1">21091279</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Dec 3;373(23):2237-46</RefSource><PMID Version="1">26624850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2014 Dec;69(12):3368-71</RefSource><PMID Version="1">25125679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Apr 24;26(7):825-31</RefSource><PMID Version="1">22301411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Jun 1;26(9):1073-82</RefSource><PMID Version="1">22301413</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Mar 13;9(3):e90111</RefSource><PMID Version="1">24625530</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2015 Dec;2(12 ):e512-9</RefSource><PMID Version="1">26614965</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2015 Aug 15;61(4):572-80</RefSource><PMID Version="1">25908682</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2014 Mar 27;28(6):851-9</RefSource><PMID Version="1">24499951</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015502" MajorTopicYN="N">Absorptiometry, Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001847" MajorTopicYN="N">Bone Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068679" MajorTopicYN="N">Emtricitabine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018451" MajorTopicYN="N">Homosexuality, Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="Y">Pre-Exposure Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28639995</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000001475</ArticleId><ArticleId IdType="pmc">PMC5597476</ArticleId><ArticleId IdType="mid">NIHMS884871</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Anderson, Peter L" sort="Anderson, Peter L" uniqKey="Anderson P" first="Peter L" last="Anderson">Peter L. Anderson</name><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda Gail" last="Bekker">Linda Gail Bekker</name><name sortKey="Buchbinder, Susan P" sort="Buchbinder, Susan P" uniqKey="Buchbinder S" first="Susan P" last="Buchbinder">Susan P. Buchbinder</name><name sortKey="Chariyalertsak, Suwat" sort="Chariyalertsak, Suwat" uniqKey="Chariyalertsak S" first="Suwat" last="Chariyalertsak">Suwat Chariyalertsak</name><name sortKey="Grant, Robert M" sort="Grant, Robert M" uniqKey="Grant R" first="Robert M" last="Grant">Robert M. Grant</name><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name><name sortKey="Guanira, Juan" sort="Guanira, Juan" uniqKey="Guanira J" first="Juan" last="Guanira">Juan Guanira</name><name sortKey="Mcmahan, Vanessa" sort="Mcmahan, Vanessa" uniqKey="Mcmahan V" first="Vanessa" last="Mcmahan">Vanessa Mcmahan</name><name sortKey="Mulligan, Kathleen" sort="Mulligan, Kathleen" uniqKey="Mulligan K" first="Kathleen" last="Mulligan">Kathleen Mulligan</name><name sortKey="Schechter, Mauro" sort="Schechter, Mauro" uniqKey="Schechter M" first="Mauro" last="Schechter">Mauro Schechter</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Glidden, David V" sort="Glidden, David V" uniqKey="Glidden D" first="David V" last="Glidden">David V. Glidden</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28639995
|texte= Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28639995" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |